[Form 4] AbCellera Biologics Inc. Insider Trading Activity

Rhea-AI Filing Summary

AbCellera Biologics Inc. director Sandor Victor received a grant of options covering 152,207 common shares on July 1, 2026. These share options have an exercise price of $7.85 per share and expire on July 1, 2036.

The options vest in three substantially equal annual installments, with the first tranche scheduled to vest on July 1, 2027, subject to his continued service with the company. After this grant, he holds options on 152,207 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sandor Victor

Role null

Type	Security	Shares	Price	Value
Grant/Award	Share option (right to buy)	152,207	$0.00	--

Holdings After Transaction: Share option (right to buy) — 152,207 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 152,207 options Exercise price: $7.85 per share Underlying shares: 152,207 common shares +3 more

6 metrics

Options granted 152,207 options Grant on July 1, 2026 to director Sandor Victor

Exercise price $7.85 per share Conversion or exercise price of granted options

Underlying shares 152,207 common shares Each option corresponds to one AbCellera common share

Expiration date July 1, 2036 Option expiration date for this grant

Post-grant option holdings 152,207 options Total derivative holdings following the transaction

First vesting date July 1, 2027 First of three annual vesting tranches, per footnote

Key Terms

Share option (right to buy), exercise price, vest and become exercisable, expiration date, +1 more

5 terms

Share option (right to buy) financial

"security_title: "Share option (right to buy)" for the reported transaction"

exercise price financial

"conversion_or_exercise_price of 7.8500 per underlying common share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares subject to such option vest and become exercisable annually in substantially equal installments"

expiration date financial

"expiration_date is listed as 2036-07-01T00:00:00.000Z for this option grant"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Common Shares financial

"underlying_security_title is identified as "Common Shares" for the option"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/06/2026 - 06:05 PM Accepted by SEC EDGAR 07/06/2026 - 06:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandor Victor

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share option (right to buy)	$7.85	07/01/2026		A	V	152,207		(1)	07/01/2036	Common Shares	152,207	$0	152,207	D

Explanation of Responses:

1. The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on July 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

	Tryn Stimart, attorney-in-fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)